NLS Pharmaceutics Ltd. Warrant (NLSPW) Financials
Newest figures come from the 10-K for FY2025, filed Apr 29, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NLSPW SEC filings page.
This page shows NLS Pharmaceutics Ltd. Warrant (NLSPW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
NLS Pharmaceutics Ltd. Warrant does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
NLS Pharmaceutics Ltd. Warrant passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
NLS Pharmaceutics Ltd. Warrant reported a net loss of $8.3M while operations used $2.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2025.
Cash & Balance Sheet
NLS Pharmaceutics Ltd. Warrant held $2.2M in cash as of Q4 2025; long-term debt is not reported for that period.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
None of these metrics is reported for Q4 2025.
NLSPW Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
NLSPW Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q2'2510-Q | Q4'2410-K | Q2'24 | Q4'23 | Q2'23 | Q4'22 | Q2'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $11.4M+1167.4% | $4.3M+263.5% | $903K-51.1% | $1.2M-47.4% | $1.8M-80.1% | $2.3M+10.3% | $9.3M+60.9% | $2.1M-75.1% |
| Current Assets | $3.2M+307.9% | $4.0M+238.4% | $780K-57.2% | $1.2M-46.9% | $1.8M-80.3% | $2.2M+11.0% | $9.2M+61.6% | $2.0M-75.5% |
| Cash & Equivalents | $2.2M+238.6% | $3.1M+455.8% | $650K-43.3% | $553K-66.5% | $1.1M-87.2% | $1.7M+22.0% | $8.9M+64.8% | $1.4M-80.9% |
| Goodwill | $1.7M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $4.2M-52.9% | $1.5M-86.1% | $8.9M+192.4% | $10.5M+59.6% | $3.0M-66.8% | $6.6M+7.5% | $9.2M+75.5% | $6.1M+51.7% |
| Current Liabilities | $4.2M-52.9% | N/A | $8.9M | $7.7M+98.3% | N/A | $3.9M+14.1% | $3.4M+39.8% | $3.4M+185.9% |
| Non-Current Liabilities | $0 | N/A | $0-100.0% | $2.7M+3.0% | $2.8M-52.5% | $2.7M-0.9% | $5.8M+106.0% | $2.7M-4.9% |
| Total Equity | $7.3M+190.7% | $2.9M+131.1% | -$8.0M-568.0% | -$9.3M-116.2% | -$1.2M-1178.4% | -$4.3M-6.1% | $111K-79.5% | -$4.0M-195.1% |
| Retained Earnings | -$84.9M-10.8% | -$74.8M-3.3% | -$76.6M-8.8% | -$72.4M-10.0% | -$70.4M-20.9% | -$65.8M-30.7% | -$58.2M-39.6% | -$50.3M-46.5% |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Accounts Receivable, Long-Term Investments, Long-Term Debt.
NLSPW Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
NLSPW Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.
Note: The current ratio is below 1.0 (0.76), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| NLS Pharmaceutics Ltd. Warrant NLSPW | FY2025 | N/A | -$8.3M | N/A | N/A | — |
| Tevogen Inc. Warrant TVGNW | FY2025 | N/A | N/A | N/A | N/A | — |
| BriaCell Therapeutics Corp. Warrant BCTXW | FY2025 | N/A | -$26.3M | N/A | N/A | — |
| Estrella Immunopharma, Inc. Warrant ESLAW | FY2025 | N/A | -$13.1M | N/A | N/A | — |
| Pasithea Therapeutics Corp. Warrants KTTAW | FY2025 | N/A | -$20.4M | N/A | N/A | — |
Where NLS Pharmaceutics Ltd. Warrant Ranks
Frequently Asked Questions
Is NLS Pharmaceutics Ltd. Warrant profitable?
No, NLS Pharmaceutics Ltd. Warrant (NLSPW) reported a net income of -$8.3M in fiscal year 2025.
What is NLS Pharmaceutics Ltd. Warrant's EBITDA?
NLS Pharmaceutics Ltd. Warrant (NLSPW) had EBITDA of -$2.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is NLS Pharmaceutics Ltd. Warrant's return on equity (ROE)?
NLS Pharmaceutics Ltd. Warrant (NLSPW) has a return on equity of -114.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is NLS Pharmaceutics Ltd. Warrant's free cash flow?
NLS Pharmaceutics Ltd. Warrant (NLSPW) recorded an outflow of $2.8M in free cash flow during fiscal year 2025. This represents a -158.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is NLS Pharmaceutics Ltd. Warrant's operating cash flow?
NLS Pharmaceutics Ltd. Warrant (NLSPW) recorded an outflow of $2.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are NLS Pharmaceutics Ltd. Warrant's total assets?
NLS Pharmaceutics Ltd. Warrant (NLSPW) had $11.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are NLS Pharmaceutics Ltd. Warrant's capital expenditures?
NLS Pharmaceutics Ltd. Warrant (NLSPW) invested $8K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does NLS Pharmaceutics Ltd. Warrant spend on research and development?
NLS Pharmaceutics Ltd. Warrant (NLSPW) invested $1.1M in research and development during fiscal year 2025.
What is NLS Pharmaceutics Ltd. Warrant's current ratio?
NLS Pharmaceutics Ltd. Warrant (NLSPW) had a current ratio of 0.76 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is NLS Pharmaceutics Ltd. Warrant's debt-to-equity ratio?
NLS Pharmaceutics Ltd. Warrant (NLSPW) had a debt-to-equity ratio of 0.58 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is NLS Pharmaceutics Ltd. Warrant's return on assets (ROA)?
NLS Pharmaceutics Ltd. Warrant (NLSPW) had a return on assets of -72.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does NLS Pharmaceutics Ltd. Warrant's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, NLS Pharmaceutics Ltd. Warrant (NLSPW) held $2.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $2.8M over that year. Dividing the one by the other, the reported balance equals about 10 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is NLS Pharmaceutics Ltd. Warrant's Piotroski F-Score?
NLS Pharmaceutics Ltd. Warrant (NLSPW) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are NLS Pharmaceutics Ltd. Warrant's earnings high quality?
NLS Pharmaceutics Ltd. Warrant (NLSPW) reported a net loss of $8.3M while operations used $2.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.